Having trouble accessing articles? Reset your cache.

Approval of first targeted sickle cell therapy heralds arrival of new agents

Scoring approval about two months ahead of its PDUFA date, Adakveo crizanlizumab-tmca from Novartis AG (NYSE:NVS; SIX:NOVN) is the first targeted sickle cell therapy approved by FDA, designed to cut the disease’s pathology at the root.

Read the full word article

User Sign In

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers